Neurocrine Biosciences, Inc.
NBIX
$102.88
-$5.43-5.01%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.20% | 56.20% | -31.94% | 156.66% | 65.96% |
| Total Depreciation and Amortization | 24.56% | 18.18% | 43.14% | 24.00% | 29.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.66% | 101.16% | 300.69% | 505.13% | -53.24% |
| Change in Net Operating Assets | 275.61% | -90.43% | -192.40% | 45.04% | -3,480.00% |
| Cash from Operations | 96.36% | -25.47% | -64.03% | 204.07% | -13.64% |
| Capital Expenditure | -35.19% | -6.58% | -70.59% | -31.76% | -200.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 68.94% | 136.57% | 86.06% | -30.36% | -176.23% |
| Cash from Investing | 66.15% | 125.39% | 77.60% | -30.64% | -74.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -71.75% | 40.43% | 444.83% | 752.44% | 43.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -919.21% | 40.43% | -10,203.45% | 752.44% | 43.90% |
| Foreign Exchange rate Adjustments | -200.00% | -- | -- | -- | 123.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -172.54% | 56.85% | -553.36% | 191.26% | -184.02% |
